National Graphite Corp. (NGRC)

Market Cap	6.66M
Revenue (ttm)	n/a
Net Income (ttm)	-1.97M
Shares Out	154.31M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,100
Average Volume	17,755
Open	0.0360
Previous Close	0.0360
Day's Range	0.0360 - 0.0360
52-Week Range	0.0228 - 0.0780
Beta	-2.58
RSI	50.05
Earnings Date	n/a

About Augmedix

National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications. National Graphite Corp. has a collaboration agreement with P...

• Industry: Shell Companies
• Sector: Financials
• Founded: 2006
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: NGRC